

**Supplementary File 2** STARPA trial safety outcomes

	Atorvastatin (n=31)	Placebo (n=31)
<i>Self-reported side effects</i>		
Muscle cramps or pain	10	10
Gastrointestinal symptoms	5	4
Skin and subcutaneous symptoms	4	2
Sleep problems	0	3
Cough	1	3
<i>Laboratory abnormalities</i>		
ALT elevation >3x ULN	3	0
CK >3x ULN	2	0
<i>Adverse events other, according to ICD-10 chapter</i>		
Infectious and parasitic disease	9	8
Neoplasms	1*	0
Blood and blood-forming organs and immune system disease	1	2
Endocrine, nutritional, and metabolic disease	1	1†
Mental and behavioral disorder	0	1
Nervous system	1	1
Eye and adnexa	0	3
Respiratory disease	1	4
Digestive system	2	1
Musculoskeletal and connective tissue disease	1	1
Genitourinary system disease	1	1
Symptoms, signs, and abnormal clinical and laboratory findings not classified elsewhere	2	3
Injury	3	1
None	8	11

\* Serious adverse event. Diagnosis metastasized colon carcinoma

† = Serious adverse event. One night of hospitalization due to abdominal pain, not diagnosed

Both SAEs were not considered to be related to trial medication.

ULN: upper limit of normal